Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced that two of its infectious disease therapies, ZEVTERA and XACDURO, have been nominated for the 2025 Prix Galien USA Award for 'Best Pharmaceutical Product.' This prestigious award recognizes groundbreaking advancements in biopharmaceutical and medical technology.
ZEVTERA, an advanced-generation cephalosporin antibiotic, received FDA approval in April 2024. It is indicated for treating adult patients with Staphylococcus aureus bloodstream infections, including MRSA, as well as acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
XACDURO, approved by the FDA in May 2023, is the first and only antibiotic indicated for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. These nominations highlight the urgent clinical needs addressed by Innoviva's therapies and the strength of its scientific innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.